2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Medtronic company profile · cardiovascular, neuroscience & medical surgical devices · history · financial snapshot · S&P 500 rank #95 · 美敦力公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | MDT (NYSE) |
| Company | Medtronic plc |
| GICS sector / industry | Health Care (XLV) / Health Care Equipment |
| S&P 500 rank (by weight) | #95 · 0.18% (Oct 29, 2026) |
| Sector rank (by market cap) | #15 in Health Care (Oct 29, 2026) |
| Headquarters | Galway, Ireland |
| Founded | 1949, in Minneapolis, Minnesota |
| CEO | Geoff Martha (chairman and CEO) |
| Employees | 95,000+ (FY2026) |
| Market cap | $124.22B (Oct 29, 2026) · price $97.11 |
| SEC filings | EDGAR — CIK 0001613103 |
WHAT IT DOES
Medtronic is the world’s largest pure-play medical device company, selling device-based therapies to hospitals and physicians in more than 150 countries. FY2026 net sales were $36.36B, up 8.4% as reported and 5.8% organically — the highest annual growth in a decade — on a fiscal year ended Apr 24, 2026.
Cardiovascular is the largest portfolio at $13.98B, led by cardiac rhythm and heart failure devices and by pulsed-field ablation (PFA) for atrial fibrillation, where cardiac ablation revenue surged 78% in Q4 FY2026. Neuroscience ($10.30B) covers cranial and spinal products, specialty therapies and neuromodulation; Medical Surgical ($8.80B) covers surgical and endoscopy products and acute care and monitoring.
The strategic story is focus: Medtronic separated Diabetes (FY2026 sales $3.11B) via the MiniMed IPO in March 2026, leaving three reportable portfolios, and is betting that PFA, structural heart and neuromodulation product cycles can sustain mid-single-digit organic growth against procedure-volume and pricing headwinds.
BUSINESS SEGMENTS — FY2026 NET SALES BY PORTFOLIO
| Portfolio | Revenue | Share | YoY |
|---|---|---|---|
| Cardiovascular | $13.98B | 38.4% | Not available |
| Neuroscience | $10.30B | 28.3% | Not available |
| Medical Surgical | $8.80B | 24.2% | Not available |
| Diabetes | $3.11B | 8.6% | Not available |
| Other | $0.17B | 0.5% | Not available |
| Total net sales | $36.36B | 100% | +8.4% |
HISTORY
| 1949 | Earl Bakken and Palmer Hermundslie found Medtronic in Minneapolis as a medical equipment repair shop |
| 1957 | Builds the first battery-powered wearable pacemaker after a power failure kills a young patient |
| 1960 | Ships the first implantable pacemaker, creating the cardiac rhythm industry |
| 2001 | Acquires MiniMed for $3.28B, entering diabetes management |
| 2014 | Announces the Covidien acquisition, the largest in Medtronic history |
| 2015 | Closes Covidien and moves its legal headquarters to Ireland |
| 2023 | PulseSelect pulsed-field ablation system wins US FDA approval |
| 2024 | Sphere-9 dual-energy catheter with Affera mapping wins US FDA approval |
| 2025 | Announces the separation of the Diabetes business as a standalone company |
| 2026 | MiniMed Group completes its initial public offering on Mar 9, 2026 |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2026
| Net sales | $36.36B (+8.4% YoY) |
| Gross profit | $23.75B |
| Operating income | $6.47B |
| Net income | $4.80B (+3.0% YoY) |
| Diluted EPS | $3.73 (GAAP) |
| Free cash flow | $5.43B |
| Total assets | $93.03B (Apr 24, 2026) |
| Research and development | Not available |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Medtronic is the S&P 500’s medical-device bellwether: at a 0.18% index weight and the #15 market cap in Health Care, it is the index’s main exposure to hospital procedure volumes and device innovation rather than to drugs.
Its PFA ramp is the sector’s most watched product cycle — ablation growth, procedure volumes and hospital capital spending show up in Medtronic results before they show up in sector aggregates.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Oct 29, 2026 crawl) |
| Financials | Medtronic FY2026 Form 10-K (SEC EDGAR, filed Jun 18, 2026) and FY2026 results release |
| Sector classification | GICS (Health Care Equipment) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | MDT(NYSE) |
| 公司 | Medtronic plc |
| GICS 板塊/行業 | 醫療保健(XLV)/醫療保健設備 |
| 標普500排名(按權重) | #95 · 0.18%(2026 年 10 月 29 日) |
| 板塊內排名(按市值) | 醫療保健第 #15(2026 年 10 月 29 日) |
| 總部 | 愛爾蘭戈爾韋 |
| 成立 | 1949 年,於明尼蘇達州明尼阿波利斯 |
| 行政總裁 | Geoff Martha(主席兼行政總裁) |
| 員工 | 95,000+(FY2026) |
| 市值 | $124.22B(2026 年 10 月 29 日)· 價格 $97.11 |
| SEC 申報 | EDGAR — CIK 0001613103 |
業務概覽
美敦力是全球最大的純醫療器械公司,向 150 多個國家的醫院與醫生銷售器械療法。FY2026 淨銷售額為 $36.36B,按申報增長 8.4%、按有機口徑增長 5.8%,為十年來最高年度增速;財政年度截至 2026 年 4 月 24 日。
心血管為最大組合($13.98B),以心律與心衰器械及房顫脈衝電場消融(PFA)為主,其中心臟消融收入在 FY2026 第四季激增 78%。神經科學($10.30B)涵蓋顱腦與脊柱產品、專科療法與神經調控;醫療外科($8.80B)涵蓋外科與內窺鏡產品及急症護理與監護。
戰略主線是聚焦:美敦力於 2026 年 3 月通過 MiniMed 上市分拆糖尿病業務(FY2026 銷售額 $3.11B),剩下三個報告組合,並押注 PFA、結構性心臟與神經調控產品週期能抵禦手術量與定價壓力,維持中個位數有機增長。
業務板塊 — FY2026 淨銷售額(按組合)
| 組合 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 心血管 | $13.98B | 38.4% | Not available |
| 神經科學 | $10.30B | 28.3% | Not available |
| 醫療外科 | $8.80B | 24.2% | Not available |
| 糖尿病 | $3.11B | 8.6% | Not available |
| 其他 | $0.17B | 0.5% | Not available |
| 淨銷售額總計 | $36.36B | 100% | +8.4% |
歷史沿革
| 1949 | Earl Bakken 與 Palmer Hermundslie 在明尼阿波利斯創立美敦力,起初為醫療設備維修店 |
| 1957 | 一名年輕病人因停電身亡後,研製首台電池供電可穿戴起搏器 |
| 1960 | 推出首台植入式起搏器,開創心律管理行業 |
| 2001 | 以 $3.28B 收購 MiniMed,進入糖尿病管理領域 |
| 2014 | 宣布收購 Covidien,為美敦力史上最大交易 |
| 2015 | 完成收購 Covidien,法定總部遷至愛爾蘭 |
| 2023 | PulseSelect 脈衝電場消融系統獲美國 FDA 批准 |
| 2024 | Sphere-9 雙能量導管連 Affera 標測系統獲美國 FDA 批准 |
| 2025 | 宣布將糖尿病業務分拆為獨立公司 |
| 2026 | MiniMed Group 於 2026 年 3 月 9 日完成首次公開發售 |
競爭地位
財務快照 — FY2026
| 淨銷售額 | $36.36B(同比 +8.4%) |
| 毛利 | $23.75B |
| 營業利潤 | $6.47B |
| 淨利潤 | $4.80B(同比 +3.0%) |
| 攤薄每股盈利 | $3.73(GAAP) |
| 自由現金流 | $5.43B |
| 總資產 | $93.03B(2026 年 4 月 24 日) |
| 研發支出 | Not available |
主要風險
對標普500的重要性
美敦力是標普500中的醫療器械風向標:指數權重 0.18%、醫療保健板塊市值第 #15,是指數對醫院手術量與器械創新而非藥品的主要敞口。
其 PFA 爬坡是行業最受關注的產品週期——消融增長、手術量與醫院資本開支,往往先在美敦力業績中出現,再反映到行業總量。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 29 日抓取) |
| 財務 | 美敦力 FY2026 Form 10-K(SEC EDGAR,2026 年 6 月 18 日申報)及 FY2026 業績公告 |
| 板塊分類 | GICS(醫療保健設備),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-30 04:31 · updated 2026-11-14 23:49 · rev 7